TONGUE RETAINING DEVICE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

In February 2021, Signifier Medical Technologies Ltd, an innovation in the sleep-disordered breathing sector, announced that the U.S. Food and Drug Administration has approved the commercialization of a novel prescription-only device designed to alleviate snoring and moderate obstructive sleep apnea. eXciteOSA is the first of its type, a daytime treatment for snoring and moderate obstructive sleep apnea (OSA). The eXciteOSA therapy, used for only 20 minutes per day for six weeks and then twice per week thereafter for maintenance, is clinically demonstrated to enhance sleep quality by drastically lowering moderate OSA and snoring.